StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

kopsource · Nov 28, 2022 15:12

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research note published on Friday morning. The firm issued a sell rating on the medical technology company's stock.

Several other brokerages have also commented on BIOL. Maxim Group decreased their price objective on shares of BIOLASE from $10.00 to $5.00 in a report on Friday, November 11th. Benchmark decreased their price objective on shares of BIOLASE to $7.00 in a report on Wednesday, November 16th. Finally, Ascendiant Capital Markets decreased their price objective on shares of BIOLASE to $14.00 in a report on Wednesday, November 16th.

Get BIOLASE alerts:

BIOLASE Stock Up 4.6 %

Shares of NASDAQ BIOL opened at $1.02 on Friday. The company has a current ratio of 2.46, a quick ratio of 1.27 and a debt-to-equity ratio of 0.92. BIOLASE has a 12 month low of $0.93 and a 12 month high of $13.83. The firm has a market capitalization of $7.25 million, a PE ratio of -0.28 and a beta of 1.45. The firm has a fifty day simple moving average of $2.01 and a two-hundred day simple moving average of $3.51.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Commonwealth Equity Services LLC increased its stake in shares of BIOLASE by 117.8% in the 1st quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company's stock worth $35,000 after acquiring an additional 54,650 shares in the last quarter. Capital Wealth Alliance LLC purchased a new stake in BIOLASE during the 2nd quarter valued at about $51,000. Citadel Advisors LLC purchased a new stake in BIOLASE during the 2nd quarter valued at about $118,000. State Street Corp grew its position in BIOLASE by 4.5% during the 1st quarter. State Street Corp now owns 436,076 shares of the medical technology company's stock valued at $154,000 after purchasing an additional 18,682 shares during the last quarter. Finally, Essex Investment Management Co. LLC grew its position in BIOLASE by 62.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 105,318 shares of the medical technology company's stock valued at $256,000 after purchasing an additional 40,440 shares during the last quarter. 21.21% of the stock is currently owned by institutional investors.

BIOLASE Company Profile

(Get Rating)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

BIOLASE Stock Up 4.6 %

Institutional Inflows and Outflows

BIOLASE Company Profile

Further Reading

Risk Disclaimer